News
Oncoinvent presents corporate update in live webcast
Oncoinvent ASA: Notice of Annual General Meeting
Oncoinvent ASA: Invitation to business update Wednesday 29 April 2026
Oncoinvent ASA: Annual Report for 2025
Oncoinvent secures new patent expanding protection for Radspherin[®]
Oncoinvent ASA: Grant of share options to the CEO
Oncoinvent ASA: Second half 2025 results
Oncoinvent to Present Positive 24-month Follow-up Data from Phase 1 Ovarian Cancer Study of Radspherin[®] at ESGO 2026
Oncoinvent ASA: Announces webcast presentation of second half 2025 results on Thursday 26 February 2026
